Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation (GNLX)
Company Research
Source: GlobeNewswire
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates. “The past quarter has continued to be transformative for the company as we completed a key financing expected to provide runway through three trial readouts, including our ongoing Phase 3 trial in platinum resistant/refractory ovarian cancer,” said Thomas Zindrick, President, Chairman and CEO of Genelux. “Beyond our pivotal Phase 3 trial, we look to provide interim data for systemic delivery of Olvi-Vec in both small and non-small cell lung cancer in the next 12 months.” The Company anticipates announcing interim results from the Phase 2 trial in recurrent non-small cell lung cancer by mid-2025, with interim data from our Phase 1b trial in recurrent small cell lung cancer expected later this year. Both trials involve the intravenous adm
Show less
Read more
Impact Snapshot
Event Time:
GNLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNLX alerts
High impacting Genelux Corporation news events
Weekly update
A roundup of the hottest topics
GNLX
News
- Genelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswire
- Genelux Co. (NASDAQ: GNLX) was upgraded by analysts at Roth Capital to a "strong-buy" rating.MarketBeat
- Genelux Co. (NASDAQ: GNLX) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Genelux Co. (NASDAQ: GNLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds [Yahoo! Finance]Yahoo! Finance
GNLX
Earnings
- 8/14/24 - Miss
GNLX
Sec Filings
- 9/26/24 - Form 4/A
- 9/13/24 - Form 4
- 9/12/24 - Form 4
- GNLX's page on the SEC website